Syros Pharmaceuticals Inc (SYRS)
Drugs • Health Care
March 21, 2025 SWOT Analysis of Syros Pharmaceuticals Inc. in 2025 This SWOT analysis examines Syros Pharmaceuticals Inc. in 2025, detailing its strengths like a strong IP portfolio, weaknesses including financial challenges, opportunities in precision medicine, and threats from competition. The company is well-positioned but must navigate significant hurdles to achieve growth.
February 28, 2025 Syros Pharmaceuticals Announces Voluntary Delisting from Nasdaq and SEC Deregistration Syros Pharmaceuticals has announced its voluntary delisting from Nasdaq and SEC deregistration following financial difficulties and compliance issues. This strategic move aims to preserve resources amid recent trial setbacks and an orderly wind-down of operations.
October 31, 2024 Syros Pharmaceuticals Inc. Reports Q3 2024 Financial Results: A Deep Dive into the Numbers Syros Pharmaceuticals Inc. reported its Q3 2024 financial results, showing no revenue and a net income loss of $26.7 million. The company is focused on advancing tamibarotene for higher-risk myelodysplastic syndrome, with pivotal trial data expected soon. Financial management and funding will be crucial as they aim to navigate operational challenges.
July 31, 2024 Syros Pharmaceuticals Inc. Reports Q2 2024 Financial Results: A Step Forward Amid Challenges Syros Pharmaceuticals Inc. announced its Q2 2024 financial results, emphasizing progress in clinical trials for tamibarotene. Despite no revenue and financial challenges, the company secured Fast Track designation from the FDA, aiming for significant advancements in hematologic malignancies.
May 14, 2024 Syros Pharmaceuticals Inc. Reports 2024 Q1 Financial Results: A Focus on Clinical Advancements Amidst Financial Challenges Syros Pharmaceuticals Inc. reported its Q1 2024 financial results, showing a net loss of $30.68 million while advancing key clinical trials for hematologic malignancies. Despite financial challenges, promising data from their trials offers hope for future developments.
March 27, 2024 Syros Pharmaceuticals Inc. Reports 2023 Annual Results: A Year of Challenges and Progress Syros Pharmaceuticals Inc. reports financial struggles in 2023, with a significant net loss and decreased revenue. Despite these challenges, the company is advancing pivotal clinical trials for its lead product, tamibarotene, aiming to improve treatment options for patients with blood disorders.